Structural and molecular investigation of small molecule reactivation of p53
Structural and molecular investigation of small molecule reactivation of p53
批准号:
8970548
负责人:
Bradley Dale Gallent
金额:
$4.86万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-03-01 至 2018-02-28
关键词:
Amino Acid SubstitutionAmino AcidsApoptosisBindingCancer PatientCell CycleCell Cycle ArrestCellsChemicalsClinicClinical TrialsComplexDNADNA BindingDNA Binding DomainDNA RepairDataDevelopmentDiagnosisElectrophoretic Mobility Shift AssayGene TargetingGenesGoalsHumanIn VitroInvestigationKnowledgeLeadLengthMalignant NeoplasmsMethodsMissense MutationModificationMolecularMutateMutationPatientsPharmacologic SubstancePhase I/II TrialPhysiologicalProtein p53ProteinsResearchScanningStructureSystemTP53 geneTechniquesTemperatureTestingTissuesTranslatingTumor Suppressor ProteinsX-Ray CrystallographyZincanaloganti-cancer therapeuticbasecancer cellcancer therapydesignfallsfunctional restorationhigh throughput screeningimprovedinsightloss of functionmeltingmethyl groupmutantpromoterpublic health relevancescaffoldsmall moleculetargeted treatmenttranscription factor
中文摘要
描述(申请人提供):抑癌基因P53是一种重要的细胞周期调节转录因子,是人类癌症中突变最多的基因1,2。这些P53癌症突变大多导致DNA结合区的单一氨基酸替换,导致全长P53蛋白持续表达,伴随着单一氨基酸的改变。这些P53 DNA结合结构域错义突变中最常见的R175H会导致蛋白质在生理温度1,3,5,20下高度不稳定和无功能。一种可以将内源性P53功能恢复到R175H或任何这些单一氨基酸突变的药物可能会对我们的癌症治疗产生巨大影响。在开发了高通量筛选后,我们发现了一个小分子,它能够稳定R175H DNA结合域,并诱导癌细胞中R175H依赖的细胞周期停滞。我们的目标是利用结构和分子技术来了解这种小分子对突变的p53的影响,以及它如何能够恢复其正常功能。我们正在用X射线结晶学研究R175H与其结合后引起的结构变化。这将使我们了解使其稳定和重新激活P53的机制。通过与R175H结合的小分子的这种相同结构,我们也将能够深入了解使其与P53结合的分子相互作用。有了这些相互作用的知识,我们和其他人就可以开始对这种分子支架进行量身定做的修改,以提高其结合能力和有效性。目前正在进行研究,以确定这种小分子是否能够恢复R175H的正常DNA结合活性,或者观察到的重新激活是否通过另一种机制。我们还在探索该分子的化学类似物对R175H和其他常见错义突变的影响。根据我们目前的数据,我们假设这个小分子能够与P53 DNA结合域的锌协调区结合,稳定蛋白质-DNA界面,并允许该突变体重新获得转录活性。我们预计这个小分子和它的几个类似物将能够结合和恢复其他构象的P53DNA结合域突变体的功能。
英文摘要
DESCRIPTION (provided by applicant): The tumor suppressor p53 is an important cell cycle regulating transcription factor which is the most mutated gene in human cancers1,2. Most of these p53 cancer mutations cause a single amino acid substitution in the DNA-binding domain, leading to continued expression of full length p53 protein with a single amino acid alteration. The most common of these p53 DNA-binding domain missense mutations, R175H, causes the protein to be highly destabilized and nonfunctional at physiological temperatures1,3,5,20. A pharmaceutical which can restore endogenous p53 function to R175H or any of these single amino acid mutations could have an enormous impact on our treatment of cancer. After developing a high throughput screen, we have discovered a small molecule which is able to stabilize the R175H DNA-binding domain and induce R175H-dependent cell cycle arrest in cancer cells. Our goal is to use structural and molecular techniques to understand the effects of this small molecule on mutant p53 and how it is able to restore its normal function. We are investigating the structural changes in R175H induced upon its binding using X-ray crystallography. This will allow us to understand the mechanism which allows it to stabilize and reactivate p53. Through this same structure of the small molecule bound to R175H we will also be able to gain insight into the molecular interactions which allow it to bind p53. With knowledge of these interactions, we and others can then begin to make tailored modifications to this molecular scaffold in order to improve its binding and efficacy. Studies are being done to determine if this small molecule is able to restore normal DNA-binding activity to R175H, or if the observed reactivation is through another mechanism. We are also exploring the effects of chemical analogs of this molecule on R175H and other common missense mutations. Based on our current data, we hypothesize that this small molecule is able to bind to the zinc-coordinating region of the p53 DNA-binding domain, stabilizing the protein-DNA interface and allowing this mutant to regain transcriptional activity. We anticipate that this small molecule and several of it analogs will be able to bind and restore function to other conformational p53 DNA-binding domain mutants.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Structural and molecular investigation of small molecule reactivation of p53
-
批准号:8650138
-
项目类别:
-
资助金额:$3.6万
-
财政年份:2015
-
负责人:Bradley Dale Gallent
-
依托单位:
Structural and molecular investigation of small molecule reactivation of p53
-
批准号:9210062
-
项目类别:
-
资助金额:$4.9万
-
财政年份:2015
-
负责人:Bradley Dale Gallent
-
依托单位:
海外基金